Fundamentals-based quality & risk · not a recommendation
Raw blend 44 capped to 40 by a red flag.
Raw blend 44 → capped to 40
Balaxi Pharmaceuticals Limited scores 40/100 (Caution) on the Orion Score — moderate business quality (53), poor growth (16), moderate balance-sheet safety (52) and fair valuation (44). A fundamentals-based quality & risk score, not a buy/sell recommendation.
Risk checks
Forensic accounting
Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check
Technical / Momentum
Price Trend
37/100
Technical momentum companion — separate from the fundamentals-based Orion Score.
Unlock with Pro
Upgrade →Q4 FY2026
Revenue & Profit in ₹ Crores
| Quarter | Revenue | Net Profit | OPM | EPS |
|---|---|---|---|---|
| Q3 2026 | ₹72.54 | ₹0.3 | 3.5% | ₹0.06 |
| Q2 2026 | ₹56.18 | ₹0.21 | 1.2% | ₹0.04 |
| Q1 2026 | ₹70.74 | ₹0.29 | 5.2% | ₹0.05 |
| Q4 2025 | ₹76.27 | ₹8.64 | 17.3% | — |
| Q3 2025 | ₹73.29 | ₹5.36 | 4.8% | ₹0.97 |
Revenue & Profit in ₹ Crores (Yearly)
| Year | Revenue | Net Profit | EBITDA | OPM |
|---|---|---|---|---|
| FY 2025 | ₹292.56 | ₹25.07 | ₹33.5 | 12.4% |
| FY 2024 | ₹241.29 | ₹-2.39 | ₹5.79 | 19.0% |
| FY 2023 | ₹336.43 | ₹45.96 | ₹59.17 | 16.5% |
| FY 2022 | ₹279.39 | ₹47.66 | ₹55.18 | 18.0% |
Top companies in the same sector by market cap
| Company | Mkt Cap | P/E | ROCE | ROE | D/E | OPM |
|---|---|---|---|---|---|---|
| BALAXI ★ | ₹133 Cr | 92.96 | 2.32% | 0.59% | 0.23x | -0.74% |
| SUNPHARMA | ₹4,27,609 Cr | 37.32 | 15.73% | 14.72% | 0.06x | 18.90% |
| MAXHEALTH | ₹95,110 Cr | 66.21 | 11.94% | 14.33% | 0.32x | 22.56% |
| AUROPHARMA | ₹90,029 Cr | 25.94 | 12.55% | 9.93% | 0.21x | 15.11% |
| ABBOTINDIA | ₹57,724 Cr | 36.63 | 36.14% | 34.46% | 0.04x | 27.01% |
| AJANTPHARM | ₹41,836 Cr | 39.55 | 27.99% | 25.39% | 0.06x | 51.40% |
All values in ₹ Crores
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total Assets | ₹310.34 | ₹258.34 | ₹239.67 | ₹176.47 |
| Equity | ₹231.74 | ₹201.36 | ₹182.88 | ₹113.16 |
| Total Debt | ₹53.43 | ₹19.4 | ₹13.31 | ₹3.64 |
| Cash | ₹39.4 | ₹62.29 | ₹28.22 | ₹7.19 |
| Net Debt | ₹12.22 | — | — | — |
| Working Capital | ₹188.23 | ₹155.97 | ₹140.38 | ₹77.74 |
Q3 FY2026
Quarter-over-Quarter Trend
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Q3 FY2026 | 65.99% | 1.74% ↓ | 0.02% | 32.24% ↑ |
| Q2 FY2026 | 65.99% | 3.5% ↓ | 0.02% | 30.49% ↑ |
| Q1 FY2026 | 65.99% | 8.87% ↓ | 0.02% | 25.12% ↑ |
| Q4 FY2025 | 65.99% | 16.02% ↓ | 0.02% | 17.96% ↑ |
| Q3 FY2025 | 65.99% | 16.48% | 0.02% | 17.5% |
| Q2 FY2025 | 65.99% | 16.48% ↓ | 0.02% | 17.5% ↑ |
| Q1 FY2025 | 65.99% ↓ | 16.88% ↓ | 0.02% | 17.11% ↑ |
| Q4 FY2024 | 66.86% | 17.21% | 0.02% | 15.91% |
No recent corporate actions
Ask: "Is Balaxi Pharmaceuticals Limited stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation
Analyse with OrionGet free stock analysis, market insights, and investment ideas delivered to your inbox.
No spam. Unsubscribe anytime.
Balaxi Pharmaceuticals Limited is listed on the NSE under the Healthcare sector, Pharmaceuticals industry. ISIN: INE618N01022. Track live share price, technical analysis, RSI, MACD, PE ratio, and smart money holdings on VestAI — India's AI-powered stock analysis platform.